NCT02377648View on ClinicalTrials.gov

Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

December 31, 2020

Conditions
Cardiac Allograft Vasculopathy
Interventions
DEVICE

Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)

Placement of bioresorbable vascular scaffold in presence of at least one critical angiographic de novo lesion (DS ≥70%) or a non-critical angiographic de novo lesion (50% ≤ DS \<70%) associated with concomitant signs or symptoms of myocardial ischemia.

Trial Locations (10)

33100

Azienda Sanitaria Universitaria Integrata Di Udine (Asuiud), Udine

37126

Azienda Ospedaliera Universitaria Integrata Verona, Verona

Unknown

Azienda Ospedaliera Brotzu, Cagliari

Azienda Ospedaliera Specialistica Dei Colli, Naples

Azienda Ospedaliera Di Padova, Padua

Fondazione Irccs Policlinico San Matteo, Pavia

Azienda Ospedaliera San Camillo Forlanini, Rome

European Hospital, Rome

Cardialysis Core Laboratory For Imaging, Rotterdam

Thoraxcenter, Universtity of Rotterdam, Rotterdam

All Listed Sponsors
lead

Universita di Verona

OTHER

NCT02377648 - Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy | Biotech Hunter | Biotech Hunter